Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
The purpose of this study is to non-invasively study the reflective changes in cardiac output
 as response to fluid therapy in the pediatric moderate hypovolemia/dehydrated pediatric
 patients using sub-q rehydration using Hylenex augmented subcutaneous infusion of fluids and
 electrolytes compared to intravenous methods.
This is an open-labeled, single-center Phase IV clinical trial. The study will consist of
 patients with moderate hypovolemia/dehydration requiring parenteral rehydration. It is
 expected that this study will describe the onset or change in cardiac output using Hylenex
 augmented subcutaneous rehydration from ages 2 months up to 3 years and at a flow rate
 satisfying clinical needs, especially in reference to changes in cardiac output observed in
 standard intravenous rehydration.
Inclusion Criteria:

 -  patients presenting to the Emergency Department (ED) with moderate dehydration
 (gorelick dehydration classification : presence of 3-6 moderate signs and symptoms)
 requiring parenteral rehydration.

 -  Patient has not successfully received oral or IV fluids immediately prior to
 enrollment

 -  patient's legally authorized representative has signed the informed consent and is
 willing for the patient to receive Hylenex augmented sub-q rehydration

 Exclusion Criteria:

 -  patient in shock or a life-threatening situation

 -  immunocompromised, history of abscess or cellulitis, abscess &/or cellulitis caused by
 Methicillin-resistant Staphylococcus aureus (MRSA), family history of abscess or
 cellulitis

 -  requires IV therapy for another indication

 -  has an indwelling catheter

 -  has already received rehydration therapy by IV route within the last 48 hours or
 substantial oral fluid in the immediate time period of enrollment

 -  has a condition precluding sub-q injection or infusion site evaluation in the upper
 middle back area or at another elected site of infusion

 -  has a reason for hospital admission or extended ED stay other than dehydration

 -  has an known hypersensitivity to hyaluronidase or another ingredient in the
 formulation of Hylenex

 -  has a know hyponatremia < 130 milliequivalents per liter (mEq/L) or hypernatremia >155
 mEq/L

 -  has a know hypokalemia <3.0 mEq/L

 -  has a medical condition likely to interfere with the patients ability to fully
 complete the study protocol or the ability to have the protocol-specified assessments

 -  has a medical history, screening physical exam finding or historical clinical lab
 result that in the opinion of the investigator would preclude the patients safe
 participation in the is study or which might adversely effect the interpretation of
 the study results

 -  patient participated in a study of any investigational drug or device within 230 days
 prior to enrollment in this study